ap - arch
  • 30,00 EUR

    Making print for private purpose, storage in computer memory, no distribution rights.

  • 40,00 EUR

    Strictly for editorial, single use on a personal (nonprofit) web site, Internet portal, social media (Facebook, Instagram etc.), blog for 1 year. Not for resale. Maximum picture size 2000px.

  • 75,00 EUR

    Strictly for editorial, single use on a commercial web site, Internet portal, social media (Facebook, Instagram etc.), blog for 1 year. Not for resale. Maximum picture size 2000px.

  • 90,00 EUR

    Strictly for editorial, single use, inside of newspaper, magazine, book (including digital version), one edition, one single country. Not for resale.

Gross prices
Contact us to calculate price for another use. Prices only for online sales.
An Indian Pharmacologist examines a Swiss albino mice inside a containment facility of the Research and Development Centre of Natco Pharma Ltd. in Hyderabad, India, Wednesday, March 13, 2012. India effectively ended Bayer's monopoly on a patented cancer drug Monday, licensing a much cheaper generic under a unique law aimed at keeping costs affordable. In a decision likely to upset Western pharmaceuticals, the patent office approved Natco Pharma Ltd.'s application to produce the kidney and liver cancer treatment sorefinib. (AP Photo/Mahesh Kumar A.)
More >><< Less
ap - arch
2012-03-13
AP/East News
Associated Press
Mahesh Kumar A/AP/DEL182
120313122430
0,84MB
29cm x 40cm by 300dpi
13, 2012, A, AFFORDABLE, AIMED, ALBINO, AN, AND, APPLICATION, APPROVED, AT, BAYER, CANCER, CENTRE, CHEAPER, CONTAINMENT, COSTS, DECISION, DEVELOPMENT, DRUG, EFFECTIVELY, ENDED, EXAMINES, FACILITY, GENERIC, HYDERABAD, IN, INDIA, INDIAN, INSIDE, KEEPING, KIDNEY, KUMAR, LAW, LICENSING, LIKELY, LIVER, LTD, MAHESH, MARCH, MICE, MONDAY, MONOPOLY, MUCH, NATCO, OF, OFFICE, ON, PATENT, PATENTED, PHARMA, PHARMACEUTICALS, PHARMACOLOGIST, PRODUCE, RESEARCH, SOREFINIB, SWISS, THE, TO, TREATMENT, UNDER, UNIQUE, UPSET, WEDNESDAY, WESTERN,